To evaluate the long-term outcomes of rituximab in the treatment of pemphigus and the influence of disease duration and different dose of rituximab on the clinical response, 45 patients with refractory pemphigus treated with at least one cycle of two infusions of rituximab (375 mg/m 2 per infusion weekly) were retrospectively studied.
INTRODUCTION
Pemphigus is a potentially life-threatening autoimmune blistering disease. Systemic corticosteroids combined with other immunosuppressive agents have been the mainstay of treatment for pemphigus. However, prolonged immunosuppression can cause death with opportunistic infections. Moreover, many severe patients become refractory to these conventional treatment modalities.
Since the first use of rituximab, a chimeric immunoglobulin (Ig)G1 monoclonal antibody targeting the B-cell-specific CD20 antigen, for pemphigus vulgaris (PV) in 2002, 1 it has been used successfully to treat severe pemphigus. [2] [3] [4] The lymphoma protocol (375 mg/m 2 9 body surface area [BSA] , four infusions, weekly) and the rheumatoid arthritis (RA) protocol (1000 mg, two infusions, 15 days apart) have been commonly used. 5, 6 Also, lower doses of the lymphoma protocol (375 mg/m 2 9 BSA, two or three infusions, weekly) and the RA protocol (500 mg, two infusions, 15 days apart) have been administrated. [7] [8] [9] There are few data on the effectiveness and relapse rate of rituximab during long-term follow up, or on the use of repeated cycles of rituximab in the treatment of relapses of pemphigus. 2, 3, 6 The objective of this study was to assess the long-term efficacy, recurrence rates and safety associated with rituximab treatment in pemphigus patients for at least 2 years after the first rituximab cycle. We also evaluated the clinical response of repeated cycles of rituximab in the treatment of relapses, and the influence of disease duration and dose on the clinical response to rituximab.
METHODS

Patients and protocols
The medical records of all patients with pemphigus who attended Gangnam Severance Hospital in Seoul, Korea, from 2006 to 2015 were retrospectively reviewed. Forty-five Korean patients with pemphigus treated with at least one cycle of two infusions of rituximab (375 mg/m 2 9 BSA per infusion, weekly) and followed up more than 2 years after the first rituximab cycle were selected. Diagnoses were made based on clinical, histological, immunofluorescence and serological criteria. 10 The study was approved by the Institutional Review Board of Yonsei University, Gangnam Severance Hospital. All patients received concomitant corticosteroids or immunosuppressive therapy during rituximab treatment. Corticosteroids were gradually tapered over the following months, according to clinical conditions. Additional cycles of rituximab were intended for patients who relapsed after achieving remission. The dose of rituximab was decided by two factors: disease severity and financial reasons. The high economic burden of rituximab treatment was the main decision factor. 
RESULTS
Patient characteristics
Patient characteristics are listed in Table 1 . Among the 45 patients, 39 (87%) had PV and six (13%) had PF. The median age of disease onset was 48 years (range, 21-83). The median age at the start of the first rituximab treatment was 50 years (range, 24-83). The median disease duration before first rituximab treatment was 15.3 months (range, 1-93). The median level of the disease severity score before rituximab therapy was 10 points, suggesting that most patients had severe and/ or refractory disease.
Efficacy and relapse according to the rituximab cycles
The treatment baseline parameters and outcomes of the additional treatment cycles are listed in Table 2 .
First treatment cycle
The median duration of the follow up after the first rituximab cycle was 49.8 months (range, 27.9-103.6). After the first rituximab therapy, all 45 patients achieved CR or PR on or off minimal therapy within 8 months, with a median time of 4.2 months. Among these patients, 34 (76%) achieved CR (four off all therapy, 30 on minimal therapy) and 11 (24%) achieved PR (two off all therapy, nine on minimal therapy). The median relapse-free remission time was 21.6 months (range, 3.5-60.9).
Of the 45 patients who achieved remission after the initial cycle of rituximab, 11 patients (24%) did not relapse and remained in remission, with follow-up times ranging 25-57 months after rituximab treatment. Relapse was observed in 34 patients (76%) after a median of 17 months (range, 8.5-59.3) from the first rituximab cycle.
Further treatment cycles
The details of the additional treatment cycles are depicted in Table 2 . Twenty patients received two or more cycles, four patients received three or more cycles, and two patients received four cycles. All patients who received additional treatment cycles achieved new remissions. Decreases in the time to remission and the concomitant methylprednisolone doses were observed with progressive cycles. The rate of patients receiving concomitant immunosuppressive agents also decreased in the second cycle of rituximab, compared with the first cycle, as did the relapse rate. After the second cycle, 13 patients (65%) were in CR (all 13 on minimal therapy) and seven patients (35%) were in PR (all seven on minimal therapy). After the third cycle, three patients (75%) were in CR (all three on minimal therapy) and one patient (25%) was in PR (on minimal therapy). After a fourth cycle, two patients (100%) achieved CR (both on minimal therapy).
Comparison between patients with or without additional rituximab cycle after relapse
Of the 34 patients with relapses after the first rituximab cycle, a second rituximab cycle was begun in 20 patients, while no additional rituximab was administrated to the other 14 patients (Table 3 
Clinical efficacy of different doses of rituximab
The patients were divided into two groups to compare the efficacy of different doses of rituximab. Group 1 (n = 16) received two infusions in the first cycle of rituximab, whereas group 2 (n = 29) received three or four infusions in the first cycle of rituximab (Table 4) .
There were no significant differences between the groups with respect to sex, age, age of disease onset, clinical severity score and disease duration before rituximab. The CR rate after 6 months was significantly higher in group 2 than group 1 (90% in group 2 and 50% in group 1, P < 0.01). Even though the time to CR, relapse rate and time to relapse after rituximab showed no significant differences, group 2 had better clinical outcomes than group 1.
Clinical efficacy of different disease duration before application of rituximab
The patients were divided into two groups to compare the efficacy of different disease durations before application of rituximab. Group 1 (n = 19) had a less than 1-year disease duration before the first rituximab cycle, whereas group 2 (n = 26) had a more than 1-year disease duration before the first rituximab cycle (Table 5) . There were no significant differences between the groups in sex, age, age of disease onset and clinical severity score. Group 1 showed better outcomes in time to CR and time to relapse, although there were no statistically significant differences.
Adverse effects of treatment
Rituximab was well tolerated in all 45 patients without severe adverse effects, such as infection, hypogammaglobulinemia or neutropenia. However, two patients died following acute respiratory distress syndrome (ARDS) and gastric perforation. They were excluded from the end-point analysis, but included in the side-effect analysis.
A 29-year-old woman with PF died 1 month after the first cycle of rituximab therapy due to ARDS, which developed within 24 h of the third infusion of rituximab, although the two prior infusions of rituximab had not produced adverse effects.
The other patient was a 55-year-old man who died 3 months after rituximab therapy due to gastric perforation, which might not have been directly related with rituximab therapy.
DISCUSSION
Our study demonstrated the long-term efficacy of rituximab at a dose of 375 mg/m 2 9 BSA per infusion weekly in combination with corticosteroids in severe pemphigus, as all patients were in CR (76%) or PR (24%) within 8 months after the first cycle of rituximab. The majority of previous studies reporting on the efficacy of rituximab in patients with pemphigus used the lymphoma protocol, consisting of a single cycle of four weekly infusions of rituximab. [13] [14] [15] Although a direct comparison of remission rates between our study and prior studies is difficult to perform because of different treatment protocols and end-point definitions, a recent meta-analysis of different rituximab dosing regimens reported a 76% CR rate after one cycle of rituximab, similar to our study. 16 The median relapse-free remission time in our study was 21 months, which is comparable to the time reported in another retrospective study (19 months) . 3 Remission has lasted up to 59 months after infusion of rituximab. Although some patients can sustain long-term remission of pemphigus after rituximab treatment, we observed a 76% relapse rate at a median time of 17 months. Previously reported relapse rates vary, depending on the treatment protocol and the length of follow up. Recently, Colliou et al. reported a 77% relapse rate, comparable to our study, after a median 79-month follow-up period. 17 Taken together, we can suggest that a single cycle of rituximab may not achieve a long-standing remission for pemphigus.
In previous studies, repeat rituximab treatment was beneficial in patients who failed to achieve remission with prior infusions or who experienced relapse. 2, 3, 6, 18 In our study, all patients who received a second, third or fourth cycle of rituximab after relapse achieved new remissions. Decreases in the time to remission and the concomitant methylprednisolone doses with additional cycles of rituximab were observed. Our study supports the idea that repeat rituximab treatment in patients who relapsed after achieving remission is favorable and has a steroid-sparing effect.
In subgroup analysis to compare the outcomes between relapsed patients receiving a second cycle of rituximab and relapsed patients receiving only conventional treatment without rituximab, CR rate was almost double in patients who received rituximab retreatment (65%) than in those without additional rituximab treatment (36%) after relapse. Also, the second cycle of rituximab induced shorter median times to remission and lower relapse rates. However, there were no statistically significant differences. These results suggest that additional cycles of rituximab result in better clinical outcomes than can be achieved without additional cycles of rituximab in managing relapsed patients.
The clinical outcomes of rituximab in treating pemphigus can be influenced by many factors, including the dose of rituximab, different treatment protocols and disease duration before rituximab therapy. In this study, we also found that high-dose rituximab and short disease duration prior to rituximab can induce better clinical responses. First, we observed that the group of patients who received three or four infusions of rituximab showed better outcomes in CR rate, time to CR, relapse rate and time to relapse after rituximab than patients who received only two infusions. However, only the CR rate was significantly different between these groups. Previously, Kim et al. of our center also reported that three or more infusions of rituximab resulted in better outcomes than two infusions with respect to time to CR and relapse rate. 8 A meta-analysis of three previous studies also concluded that high-dose rituximab was associated with longer CR compared with low-dose rituximab. 16 Previous reports may be comparable to our study, but we postulated that this study can provide more reliable data in terms of relapse rate and time to relapse, because all patients were followed up for more than 2 years after rituximab therapy. We observed that early use of rituximab within 1 year of disease duration resulted in better time to CR and longer times between relapses, but these were not statistically significant differences. Previously, Lunardon et al. found that rituximab was more effective when given early in the course of disease. 3 Although further prospective clinical trials will be necessary to substantiate this observation and to determine the optimal time point to start rituximab, our results support the rationale for the early use of rituximab in the course of disease.
Severe side-effects of rituximab, including deep vein thrombosis, pulmonary embolism, hypogammaglobulinemia, neutropenia, progressive multifocal leukoencephalopathy and severe infections, have rarely been reported. [19] [20] [21] [22] [23] [24] A metaanalysis of 153 patients treated with rituximab showed that 13% of patients developed serious adverse events, with three fatalities. 24 In this study, one PF patient expired due to ARDS.
ARDS is rarely reported in rituximab therapy, and the possible mechanisms include pro-inflammatory cytokine release, complement activation and delayed hypersensitivity. 25 Considering the fact that ARDS developed within 24 h after the third infusion of rituximab, a hypersensitivity reaction to repeated infusion of rituximab might have been involved in this case.
There are limitations associated with this study, including a relatively small patient cohort and the fact that this was a retrospective, observational study without a control group. Further studies on large groups of patients with randomized controlled trials or prospective cohorts would be valuable to determine the efficacy and safety of rituximab and factors influencing the clinical outcomes of rituximab.
In conclusion, rituximab was effective and safe for the induction and maintenance of remission in patients with pemphigus. However, relapses occurred in long-term follow up at a 76% rate after at least 2 years of follow up. Additional cycles of rituximab were beneficial in treating relapses. Further prospective studies would be valuable in determining how early in the course of disease and how many cycles of rituximab will give optimal clinical outcomes.
